ATE433326T1 - Verwendung von löslichem fgl2 als immunosuppressivum - Google Patents

Verwendung von löslichem fgl2 als immunosuppressivum

Info

Publication number
ATE433326T1
ATE433326T1 AT03706150T AT03706150T ATE433326T1 AT E433326 T1 ATE433326 T1 AT E433326T1 AT 03706150 T AT03706150 T AT 03706150T AT 03706150 T AT03706150 T AT 03706150T AT E433326 T1 ATE433326 T1 AT E433326T1
Authority
AT
Austria
Prior art keywords
soluble fgl2
methods
immunosuppressant
soluble
fgl2 protein
Prior art date
Application number
AT03706150T
Other languages
English (en)
Inventor
Gary Levy
Original Assignee
Gary Levy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gary Levy filed Critical Gary Levy
Application granted granted Critical
Publication of ATE433326T1 publication Critical patent/ATE433326T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT03706150T 2002-03-01 2003-02-28 Verwendung von löslichem fgl2 als immunosuppressivum ATE433326T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36105602P 2002-03-01 2002-03-01
PCT/CA2003/000273 WO2003074068A2 (en) 2002-03-01 2003-02-28 Use of soluble fgl2 as an immunosuppressant

Publications (1)

Publication Number Publication Date
ATE433326T1 true ATE433326T1 (de) 2009-06-15

Family

ID=27789065

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03706150T ATE433326T1 (de) 2002-03-01 2003-02-28 Verwendung von löslichem fgl2 als immunosuppressivum

Country Status (7)

Country Link
US (2) US7632495B2 (de)
EP (1) EP1482961B1 (de)
AT (1) ATE433326T1 (de)
AU (1) AU2003208197A1 (de)
CA (1) CA2477312C (de)
DE (1) DE60327925D1 (de)
WO (1) WO2003074068A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048488A1 (en) * 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
CA2682429A1 (en) * 2009-05-20 2010-11-20 Gary Levy An assay for measuring plasma fgl-2 and methods and uses thereof
US9005630B2 (en) 2012-11-01 2015-04-14 Veterinaerinstituttet Fusion proteins for the treatment of allergic diseases
DK2914285T3 (en) * 2012-11-01 2017-02-27 Veterinærinstituttet New fusion proteins for the treatment of allergic diseases
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
IL296912A (en) * 2020-03-31 2022-12-01 Biond Biologics Ltd Immune-modulating preparations and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
WO1998051335A1 (en) * 1997-05-15 1998-11-19 Transplantation Technologies Inc. Methods of modulating immune coagulation
AU2003202388A1 (en) * 2002-02-07 2003-09-02 Trillium Therapeutics Inc. Porcine fgl2

Also Published As

Publication number Publication date
WO2003074068A3 (en) 2003-12-18
CA2477312A1 (en) 2003-09-12
AU2003208197A1 (en) 2003-09-16
EP1482961A2 (de) 2004-12-08
HK1071079A1 (en) 2005-07-08
CA2477312C (en) 2013-02-26
WO2003074068A2 (en) 2003-09-12
EP1482961B1 (de) 2009-06-10
US7632495B2 (en) 2009-12-15
DE60327925D1 (de) 2009-07-23
AU2003208197A8 (en) 2003-09-16
US20050164923A1 (en) 2005-07-28
US20100048486A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
DK1032662T3 (da) Fremgangsmåder og sammensætninger til immunmodulation
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
BR0011838A (pt) Elementos misturadores estáticos empilhados
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
WO2004043361A3 (en) Compositions and methods for the treatment of natural killer cell related diseases
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
EA200700213A1 (ru) Терапевтические композиции с нейротоксином ботулина
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2001068697A3 (en) Methods and compositions for immunoregulation
EA200600738A1 (ru) Способ
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
ATE433326T1 (de) Verwendung von löslichem fgl2 als immunosuppressivum
WO2005009366A3 (en) Restoring vascular function
ATE406178T1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
WO2004019965A3 (en) Thymus-based tolerogenic approaches for type i diabetes.
ATE291586T1 (de) Humanes antibiotisches protein
WO2004083241A3 (en) Btc-interacting proteins and use thereof
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
DE602004012759D1 (de) Behandlung von fibrosen
EA200400534A1 (ru) Стимуляция тимозином генетической иммунизации
ITFI20030238A1 (it) Peptidi ciclici antagonisti dell'urotensina-ii
CY1108543T1 (el) Εμβολια dna που κωδικοποιουν βοηθητικες πρωτεϊνες του hiv
ZA200407798B (en) Protein isolates, compositions comprising protein isolates and methods of use.
WO2006073760A3 (en) Regulation of mink in thymocytes and t lymphocytes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties